Please ensure Javascript is enabled for purposes of website accessibility

Why Protagonist Therapeutics Stock Plunged Today

By Keith Speights – Sep 20, 2021 at 4:14PM

Key Points

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA has placed a clinical hold on testing of rusfertide.

What happened

Shares of Protagonist Therapeutics (PTGX 3.46%) were plunging 26.3% as of 3:39 p.m. EDT on Monday. The big decline came after the company announced that the U.S. Food and Drug Administration has placed a clinical hold on studies evaluating rusfertide.

So what

The FDA's clinical hold resulted from Protagonist finding both benign and malignant skin tumors in mice in a preclinical study of rusfertide. Protagonist was testing the drug in a phase 2 study targeting treatment of polycythemia vera and other blood disorders.

A physician wearing a face mask is holding a hand up in a halting gesture.

Image source: Getty Images.

Protagonist does have two other pipeline programs in clinical testing, so all of its fortunes don't rest solely on rusfertide. The company is evaluating PN-943 in a phase 2 proof-of-concept study targeting ulcerative colitis. It's also collaborating with Johnson & Johnson on a phase 2 study of PTG-200 in treating Crohn's disease, as well as two other early stage programs.

Still, the clinical hold for rusfertide presents a major setback for Protagonist. The company had intended to report preliminary results from a phase 2 study of the drug in treating hereditary hemochromatosis, a genetic blood disorder that can cause liver disease, by year-end. It also hoped to advance rusfertide into late-stage testing in treating polycythemia vera early next year. Those plans are now up in the air.

Now what

Protagonist stated that it's working with the FDA but didn't provide any estimates as to how long the hold might be in place. The biotech stock seems likely to remain highly volatile until the clinical hold is lifted. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Stocks Mentioned

Protagonist Therapeutics, Inc. Common Stock Stock Quote
Protagonist Therapeutics, Inc. Common Stock
$8.07 (3.46%) $0.27
Johnson & Johnson Stock Quote
Johnson & Johnson
$178.88 (0.08%) $0.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.